<DOC>
	<DOC>NCT01969643</DOC>
	<brief_summary>This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer. Increasing doses of SGN-LIV1A will be given every 3 weeks alone or in combination with trastuzumab.</brief_summary>
	<brief_title>A Safety Study of SGN-LIV1A in Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Pathologically confirmed diagnosis of breast cancer with radiographic evidence of incurable, unresectable, locally advanced or metastatic disease (LA/MBC) One of the following: a) Triplenegative disease (ER/PR/HER2negative) and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting; or b) ER and/or PRpositive/HER2negative disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting and are no longer a candidate for hormonal therapy; or c) Combination Arm: HER2positive disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting. Positive for LIV1 expression by central pathology review on archival or newly obtained tumor tissue biopsy Measurable disease Eastern Cooperative Oncology Group performance status 0 or 1 Combination Arm: adequate heart function Preexisting neuropathy Grade 2 or higher Malignant CNS disease that has not been definitively treated Pgp inducers/inhibitors or strong CYP3A inducers/inhibitors within 2 weeks before first dose Combination Arm: hypersensitivity to trastuzumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Antibody-drug conjugate</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Metastatic</keyword>
	<keyword>LIV-1 protein, human</keyword>
	<keyword>Trastuzumab</keyword>
</DOC>